Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arbutus Biopharma Corp
(NQ:
ABUS
)
4.140
+0.010 (+0.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arbutus Biopharma Corp
< Previous
1
2
3
4
5
6
Next >
Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
March 14, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
March 02, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
February 16, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Biopharma's Return On Capital Employed Insights
December 12, 2022
Via
Benzinga
Recap: Arbutus Biopharma Q2 Earnings
August 04, 2022
Arbutus Biopharma (NASDAQ:ABUS) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Arbutus Biopharma: Q1 Earnings Insights
May 05, 2022
Arbutus Biopharma (NASDAQ:ABUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Arbutus to Participate in Three Upcoming Investor Conferences
February 06, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces Resignation of Board Member
January 27, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
January 05, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
December 13, 2022
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
December 06, 2022
Via
Benzinga
Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 09, 2022
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present at Jefferies London Healthcare Conference
November 08, 2022
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®
November 01, 2022
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022
October 31, 2022
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update
October 26, 2022
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End
September 30, 2022
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
September 13, 2022
Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares!
Via
InvestorPlace
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know
August 26, 2022
Moderna Inc (NASDAQ: MRNA) has
Via
Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
July 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
July 06, 2022
The company isn't seeking an injunction, but wants "fair compensation."
Via
Investor's Business Daily
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
July 05, 2022
The company isn't seeking an injunction, but wants "fair compensation."
Via
Investor's Business Daily
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
June 28, 2022
Via
Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, May 9
May 09, 2022
CNBC Ford Motor Selling 8M Shares Of Rivian Automotive
Via
Benzinga
Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ
May 09, 2022
Moderna Inc (NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 vaccine, arguing that the companies may only pursue their claims by seeking...
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Arbutus Biopharma Earnings Conference Call Is Coming Up, Here's What You Need To Know
April 28, 2022
Arbutus Biopharma (NASDAQ:ABUS) will host a conference call at 08:45 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters
March 18, 2022
Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents,
Via
Benzinga
Arbutus Biopharma Earnings Perspective: Return On Capital Employed
March 09, 2022
Benzinga Pro data, Arbutus Biopharma (NASDAQ:ABUS) reported Q4 sales of $3.21 million. Earnings fell to a loss of $21.32 million, resulting in a 11.29% decrease from last quarter...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.